Nicholas Iannotti

7.2k total citations · 1 hit paper
60 papers, 4.2k citations indexed

About

Nicholas Iannotti is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Nicholas Iannotti has authored 60 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 32 papers in Pulmonary and Respiratory Medicine and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Nicholas Iannotti's work include Cancer Immunotherapy and Biomarkers (25 papers), Lung Cancer Treatments and Mutations (18 papers) and Cancer Treatment and Pharmacology (16 papers). Nicholas Iannotti is often cited by papers focused on Cancer Immunotherapy and Biomarkers (25 papers), Lung Cancer Treatments and Mutations (18 papers) and Cancer Treatment and Pharmacology (16 papers). Nicholas Iannotti collaborates with scholars based in United States, Germany and United Kingdom. Nicholas Iannotti's co-authors include Edith P. Mitchell, Cornelis J.A. Punt, Neal J. Meropol, Michael Craig Miller, Steven J. Cohen, Kert D. Sabbath, Bruce Saidman, Joel Picus, Gerald V. Doyle and H. Tissing and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Nicholas Iannotti

59 papers receiving 4.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer

2008 1.5k citations Steven J. Cohen, Cornelis J.A. Punt et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Nicholas Iannotti

Since Specialization

Citations

This map shows the geographic impact of Nicholas Iannotti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicholas Iannotti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicholas Iannotti more than expected).

Fields of papers citing papers by Nicholas Iannotti

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicholas Iannotti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicholas Iannotti. The network helps show where Nicholas Iannotti may publish in the future.

Co-authorship network of co-authors of Nicholas Iannotti

This figure shows the co-authorship network connecting the top 25 collaborators of Nicholas Iannotti. A scholar is included among the top collaborators of Nicholas Iannotti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicholas Iannotti. Nicholas Iannotti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A PHASE 1B TRIAL OF MASOFANITEN (EPI-7386) IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) 2025 ·Urologic Oncology Seminars and Original Investigations ·(unknown), Nicholas Iannotti, Russell K. Pachynski, Bradley Curtis Carthon, Kim N., Matthew R. Smith, Fred Saad, Роберто Пили, (unknown), Edmond M. Kwan, Alexander W. Wyatt, (unknown), Brett S. Younginger, Ronan Le Moigne, Alessandra Cesano	0
2	Combination of Itacitinib or Parsaclisib with Pembrolizumab in Patients with Advanced Solid Tumors: A Phase I Study 2023 ·Cancer Research Communications ·Pamela N. Münster, Nicholas Iannotti, Daniel C. Cho, John M. Kirkwood, Liza C. Villaruz, Geoffrey T. Gibney, F. Stephen Hodi, Niharika B. Mettu, Mark Jones, (unknown), Michael Smith, Mani Lakshminarayanan, Steven O’Day	5
3	A Phase II Trial of the CD40 Agonistic Antibody Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Confirmed Disease Progression on Anti-PD-1 Therapy 2023 ·Clinical Cancer Research ·Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel‐Ángel Berciano‐Guerrero, Eva Muñoz‐Couselo, Delvys Rodríguez‐Abreu, Valentina Boni, Lynn M. Schuchter, María González‐Cao, Ana Arance, Wei Wei, Apar Kishor Ganti, Ralph J. Hauke, Alfonso Berrocal, Nicholas Iannotti, (unknown), Harriet M. Kluger	28
4	1813P Phase I/II trial of oral EPI-7386 in combination with enzalutamide (enz) compared to enz alone in metastatic castration-resistant prostate cancer (mCRPC) subjects: Current phase I (PI) results 2023 ·Annals of Oncology ·(unknown), Gurkamal Chatta, Christos E. Kyriakopoulos, Nicholas Iannotti, Sébastien J. Hotte, Mark C. Markowski, Роберто Пили, Jacqueline Vuky, Jun Zhang, Fred Saad, Karina Villaluna, Brett S. Younginger, Ronan Le Moigne, Alessandra Cesano	4
5	FIGHT-101, a first-in-human study of potent and selective FGFR 1-3 inhibitor pemigatinib in pan-cancer patients with FGF/FGFR alterations and advanced malignancies 2022 ·Annals of Oncology ·Vivek Subbiah, Nicholas Iannotti, Martin Gutierrez, David C. Smith, Luis Féliz, Christine Lihou, Chuan Tian, Ian M. Silverman, Tao Ji, Mansoor N. Saleh	125
6	JASPER: Phase 2 trial of first‐line niraparib plus pembrolizumab in patients with advanced non–small cell lung cancer 2021 ·Cancer ·Suresh S. Ramalingam, (unknown), Mark M. Awad, Afshin Dowlati, (unknown), Thomas E. Stinchcombe, Grace K. Dy, David R. Spigel, Sharon Lu, (unknown), Yongqiang Tang, (unknown), Nicholas Iannotti	58
7	Efficacy and safety of first-line avelumab in patients with advanced non-small cell lung cancer: results from a phase Ib cohort of the JAVELIN Solid Tumor study 2020 ·Journal for ImmunoTherapy of Cancer ·Claire F. Verschraegen, Guy Jérusalem, Edward F. McClay, Nicholas Iannotti, Charles H. Redfern, Jaafar Bennouna, (unknown), Karen Kelly, Janice M. Mehnert, John C. Morris, Matthew H. Taylor, David R. Spigel, Ding Wang, H. Grote, Dongli Zhou, Neru Munshi, Marcis Bajars, James L. Gulley	19
8	OA03.03 JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti-PD-L1) as First-Line Treatment in Patients with Advanced NSCLC 2017 ·Journal of Thoracic Oncology ·Guy Jérusalem, Franklin Chen, David R. Spigel, Nicholas Iannotti, Edward F. McClay, Charles H. Redfern, Jaafar Bennouna, Matthew H. Taylor, Howard L. Kaufman, Karen Kelly, Vikram K. Chand, Anja von Heydebreck, Claire F. Verschraegen	19
9	Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial 2017 ·The Lancet Oncology ·James L. Gulley, Arun Rajan, David R. Spigel, Nicholas Iannotti, Jason C. Chandler, Deborah Jean Lee Wong, Joseph W. Leach, W. Jeff Edenfield, Ding Wang, H. Grote, Anja von Heydebreck, Kevin M. Chin, Jean-Marie Cuillerot, Karen Kelly	225
10	Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody : updated analysis from the phase Ib JAVELIN solid tumor trial 2016 ·Open Repository and Bibliography (University of Liège) ·Karen Kelly, (unknown), J. R. Infante, Nicholas Iannotti, Petros Nikolinakos, Joseph W. Leach, (unknown), Jason C. Chandler, Guy Jérusalem, Jayne Gurtler, H-T. Arkenau, Marcis Bajars, Anja von Heydebreck, (unknown), (unknown), James L. Gulley	1
11	Abstract CT132: Safety of avelumab (MSB0010718C), an anti-PD-L1 antibody: updated analysis from the phase Ib JAVELIN Solid Tumor trial 2016 ·Cancer Research ·Karen Kelly, Manish R. Patel, Jeffrey R. Infante, Nicholas Iannotti, Petros Nikolinakos, Joseph W. Leach, Ding Wang, Jason C. Chandler, Guy Jérusalem, Jayne S. Gurtler, (unknown), Marcis Bajars, Anja von Heydebreck, (unknown), Christopher R. Heery, James L. Gulley	1
12	Randomized phase II study of two intercalated combinations of eribulin mesylate and erlotinib in patients with previously treated advanced non-small-cell lung cancer 2014 ·Annals of Oncology ·Tony Mok, Sarayut Lucien Geater, Nicholas Iannotti, Sumitra Thongprasert, Alexander I. Spira, David C. Smith, Victor Lee, Wan‐Teck Lim, Larisa Reyderman, (unknown), P. Gopalakrishna, (unknown), Lucy T. Xu, Craig H. Reynolds	11
13	Randomized Phase 2b Study of Pralatrexate Versus Erlotinib in Patients With Stage IIIB/IV Non–Small-Cell Lung Cancer (NSCLC) After Failure of Prior Platinum-Based Therapy 2012 ·Journal of Thoracic Oncology ·Karen Kelly, Christopher G. Azzoli, Petr Zatloukal, István Albert, Peter Jiang, David Bodkin, José Rodrigues Pereira, Erzsébet Juhász, Nicholas Iannotti, (unknown), Tony Koutsoukos, Jyoti D. Patel	26
14	Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer 2012 ·Annals of Oncology ·Charu Aggarwal, Neal J. Meropol, Cornelis J.A. Punt, Nicholas Iannotti, Bruce Saidman, Kert D. Sabbath, Nashat Gabrail, Joel Picus, Michael A. Morse, Edith P. Mitchell, Michael Craig Miller, Steven J. Cohen	143
15	A Phase II Study of Eribulin Mesylate (E7389) in Patients With Advanced, Previously Treated Non–Small-Cell Lung Cancer 2011 ·Clinical Lung Cancer ·Alexander I. Spira, Nicholas Iannotti, Michael A. Savin, Marcus A. Neubauer, Nashat Gabrail, Ronald Yanagihara, Edith Zang, Patricia E. Cole, Dale E. Shuster, Asha Das	26
16	Prognostic significance of circulating tumor cells in patients with metastatic colorectal cancer 2009 ·Annals of Oncology ·Steven J. Cohen, Cornelis J.A. Punt, Nicholas Iannotti, Bruce Saidman, Kert D. Sabbath, N. Gabrail, Joel Picus, Michael A. Morse, Edith P. Mitchell, Michael Craig Miller, Gerald V. Doyle, H. Tissing, Leon W.M.M. Terstappen, Neal J. Meropol	418
17	Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal Cancer breakdown → 2008 ·Journal of Clinical Oncology ·Steven J. Cohen, Cornelis J.A. Punt, Nicholas Iannotti, Bruce Saidman, Kert D. Sabbath, Nashat Gabrail, Joel Picus, Michael Morse, Edith P. Mitchell, Michael Craig Miller, Gerald V. Doyle, H. Tissing, Leon W.M.M. Terstappen, Neal J. Meropol	1473
18	Phase III trial comparing paclitaxel poliglumex vs docetaxel in the second-line treatment of non-small-cell lung cancer 2008 ·British Journal of Cancer ·Luis Paz‐Ares, Helen J. Ross, Mary O’Brien, A. Riviére, U. Gatzemeier, Joachim von Pawel, E. Kaukel, L Freitag, W. Digel, Helge Bischoff, Rosario García‐Campelo, Nicholas Iannotti, Pavel Reiterer, Isabel Bover, J Prendiville, Amy J. Eisenfeld, F. B. Oldham, B. Bandstra, Jack W. Singer, Philip Bonomi	125
19	Teachers' Tools for the 21st Century: A Report on Teachers' Use of Technology. 2000 ·Becky Smerdon, Stephanie Cronen, Lawrence Lanahan, Jennifer Anderson, Nicholas Iannotti, January Angeles	237
20	Phase-1 trial of high-dose intravenous cisplatin with simultaneous intravenous sodium thiosulfate 1991 ·Journal of Cancer Research and Clinical Oncology ·Maurie Markman, (unknown), Nicholas Iannotti, Mark G. Kris, Thomas B. Hakes, Dean F. Bajorin, George J. Bosl, Bonnie Reichman, Ephraim S. Casper, Gordon B. Magill, Amy Budnick	32

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact